Cargando…
Immunotherapy with PD-1 Inhibitor Nivolumab in Recurrent/Metastatic Platinum Refractory Head and Neck Cancers—Early Experiences from Romania and Literature Review
Prognosis in recurrent/metastatic head and neck squamous-cell carcinoma (HNSCC) refractory to platinum-based chemotherapy is poor, making therapy optimization a priority. Anti-programmed cell death protein 1 (anti-PD-1) monoclonal antibody Nivolumab was approved in such cases. We present the early e...
Autores principales: | Mireștean, Camil Ciprian, Stan, Mihai Cosmin, Schenker, Michael, Volovăț, Constantin, Volovăț, Simona Ruxandra, Iancu, Dragoș Teodor Petru, Iancu, Roxana Irina, Bădulescu, Florinel |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10452972/ https://www.ncbi.nlm.nih.gov/pubmed/37627878 http://dx.doi.org/10.3390/diagnostics13162620 |
Ejemplares similares
-
The Prognostic Value of Platelet–Lymphocyte Ratio, Neutrophil–Lymphocyte Ratio, and Monocyte–Lymphocyte Ratio in Head and Neck Squamous Cell Carcinoma (HNSCC)—A Retrospective Single Center Study and a Literature Review
por: Mireștean, Camil Ciprian, et al.
Publicado: (2023) -
Radiomics in Triple Negative Breast Cancer: New Horizons in an Aggressive Subtype of the Disease
por: Mireștean, Camil Ciprian, et al.
Publicado: (2022) -
Head and Neck Low Grade Chondrosarcoma—A Rare Entity
por: Mireștean, Camil Ciprian, et al.
Publicado: (2023) -
Micro-RNAs, the Cornerstones of the Future of Radiobiology in Head and Neck Cancers?
por: Mireștean, Camil Ciprian, et al.
Publicado: (2022) -
Education in Radiation Oncology—Current Challenges and Difficulties
por: Mireștean, Camil Ciprian, et al.
Publicado: (2022)